- GlucoseGlucose: Based on a clinical study in elderly patients with type II hyperlipidemia administered 10mg policosanol, octacosanol (the main component of policosanol) may significantly reduce glucose levels, but may not influence glycemic control of patients with type 2 diabetes (28; 39).
- LipidsLipids: Based on clinical studies of policosanol 5-40mg, octacosanol (the main component of policosanol) may significantly reduce total cholesterol, LDL-C, and the ratios of LDL-C to HDL-C and total cholesterol to HDL-C, and increase HDL-C (17; 46; 19; 21; 22; 48; 23; 25; 26; 10; 27; 28; 14; 11; 29; 30; 1; 33; 34; 12; 35). Based on a clinical trial using policosanol, octacosanol (the main component of policosanol) may not change triglyceride levels (19; 23; 14; 30). However, in clinical trials up to three years long, policosanol decreased triglyceride levels (28; 11; 25).
Copyright © 2011 Natural Standard (www.naturalstandard.com)
The information in this monograph is intended for informational purposes only, and is meant to help users better understand health concerns. Information is based on review of scientific research data, historical practice patterns, and clinical experience. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions.